Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
For more information, please visit the Senti Bio website at https://www.sentibio.com.
For more information, please visit the Senti Bio website at https://www.sentibio.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $169.5M
Founded date: 2016
Investors 10
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.01.2025 | - | $11.5M | - |
| 06.01.2021 | - | $105M | - |
| 27.02.2018 | Series A | $53M | New Enterp... |
Mentions in press and media 11
| Date | Title | Description |
| 06.01.2025 | Senti Bio Announces Additional $11.5 Million of Financing | – Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (... |
| 02.12.2024 | Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing | SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its propri... |
| 20.12.2021 | Dynamics Special Purpose : Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Thera... | Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies - Business combination with Dynamics Special Purpose Corp. (Na... |
| 20.12.2021 | Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies | - Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (... |
| 06.01.2021 | Senti Bio raises $105 million for its new programmable biology platform and cancer therapies | Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences giant Bayer. The company’s technology us... |
| 27.02.2018 | NEA Leads $53M Round for Senti Biosciences | Senti Biosciences, the synthetic biology company developing next-generation adaptive therapies for important diseases, today announced the completion of a $53M round of funding to support them as they expand their therapeutic design platfor... |
| 27.02.2018 | Term Sheet — Tuesday, February 27 | CO-WORKING WARS Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop That’s impressive, but it’s hard to ignore the fact that Industrious will go head to head with WeWork, the 800-pound gorill... |
| 27.02.2018 | Senti Biosciences Receives $53M | SAN FRANCISCO, CA, Senti Biosciences today announced the completion of a $53 million round of funding. >> Click here for more funding data on Senti Biosciences >> To export Senti Biosciences funding data to PDF and Excel, cl... |
| 27.02.2018 | Amgen Ventures Backs Senti Biosciences In $53M Funding | Amgen Ventures, the venture capital arm of Amgen, is one of the investors in synthetic biology startup Senti Biosciences. Senti said on Tuesday that it has raised $53M in a funding round. The funding round led by New Enterprise Associates, ... |
| 27.02.2018 | Senti Biosciences Secures $53M in Series A Funding | Senti Biosciences, a South San Francisco, Calif.-based the synthetic biology company developing adaptive therapies for important diseases, completed a $53M Series A round of funding. The round was led by New Enterprise Associates, with part... |
Show more